Preliminary Study Suggests Tuberculosis Vaccine May Reduce Risk of COVID-19 Death

Preliminary Study Suggests Tuberculosis Vaccine May Reduce Risk of COVID-19 Death

Some researchers have been perplexed by the observation that many developing countries have far less COVID-19 cases than developed nations. Luis Escobar of the College of Natural Resources and Environment from Virginia Polytechnic Institute and two associates from the National Institutes of Health now argue that Bacille Calmette-Guérin (BCG), the tuberculosis vaccine that is routinely administered to children in regions where TB rates are high, might actually contribute to fighting off COVID-19. Other principal investigators from prestigious institutions, such as Texas A&M, have also initiated major clinical trials to investigate this hypothesis.

With the results of a study recently published in the Proceedings of the National Academy of Sciences, the researchers have found compelling evidence that in countries where BCG vaccination rates are high, actual COVID-19 mortality rates are lower. The team has to statistically factor in that not all countries are the same, making adjustments to accommodate differences, reports David Fleming writing for Virginia Tech Daily. And Escobar himself has acknowledged that these findings are, in fact, quite preliminary and that considerabl...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee